{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:40:18Z","timestamp":1790185218421,"version":"4.1.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s43440-025-00799-2","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:59:40Z","timestamp":1762495180000},"page":"1491-1513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The ketogenic diet in Parkinson\u2019s disease: a potential therapeutic strategy"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1726-2174","authenticated-orcid":false,"given":"Barbara","family":"Pokora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9482-1297","authenticated-orcid":false,"given":"Kacper","family":"Pokora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1173-2966","authenticated-orcid":false,"given":"Agata","family":"Binienda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-4417","authenticated-orcid":false,"given":"Jakub","family":"Fichna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"799_CR1","doi-asserted-by":"crossref","unstructured":"Su D, Cui Y, He C, Yin P, Bai R, Zhu J, et al. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 Countries and territories to 2050: modelling study of global burden of disease study 2021. BMJ. 2025.","DOI":"10.1136\/bmj-2024-080952"},{"key":"799_CR2","unstructured":"Ray Dorsey E, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016. A systematic analysis for the global burden of disease study 2016. The Lancet Neurol. 2018;17(11)."},{"key":"799_CR3","doi-asserted-by":"crossref","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601. John Wiley and Sons Inc.","DOI":"10.1002\/mds.26424"},{"key":"799_CR4","doi-asserted-by":"crossref","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18.","DOI":"10.1038\/nrn.2017.62"},{"key":"799_CR5","doi-asserted-by":"crossref","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson\u2019s disease. The Lancet Neurology 2021;30.","DOI":"10.1016\/S1474-4422(21)00030-2"},{"key":"799_CR6","doi-asserted-by":"crossref","unstructured":"Day JO, Mullin S. The genetics of Parkinson\u2019s disease and implications for clinical practice. Genes. 2021;12.","DOI":"10.3390\/genes12071006"},{"key":"799_CR7","doi-asserted-by":"crossref","unstructured":"Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, et al. \u03b1-synuclein in Parkinson\u2019s disease: causal or bystander? J Neural Transm. 2019;126.","DOI":"10.1007\/s00702-019-02025-9"},{"key":"799_CR8","doi-asserted-by":"crossref","unstructured":"Dy\u0144ka D, Kowalcze K, Paziewska A. The role of ketogenic diet in the treatment of neurological diseases. Nutrients. 2022;14.","DOI":"10.3390\/nu14235003"},{"key":"799_CR9","doi-asserted-by":"crossref","unstructured":"Chagraoui A, Boulain M, Juvin L, Anouar Y, Barri\u00e8re G, De Deurwaerd\u00e8re P. L-DOPA in Parkinson\u2019s disease: looking at the \u201cfalse\u201d neurotransmitters and their meaning. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21010294"},{"key":"799_CR10","doi-asserted-by":"crossref","unstructured":"Sivanandy P, Leey TC, Xiang TC, Ling TC, Wey Han SA, Semilan SLA, et al. Systemic review on Parkinson\u2019s disease medications, emphasizing on three recently approved drugs to control Parkinson\u2019s symptoms. Int J Environ Res Pub Health and Public Health. MDPI. 2022;19.","DOI":"10.3390\/ijerph19010364"},{"key":"799_CR11","doi-asserted-by":"crossref","unstructured":"Riederer P, Horowski R. L-DOPA-therapy in Parkinson\u2019s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin. J Neural Transm. 2023;130.","DOI":"10.1007\/s00702-023-02692-9"},{"key":"799_CR12","doi-asserted-by":"crossref","unstructured":"Adams JD. Possible causes of Parkinson\u2019s disease. Front Biosci - Landmark. 2021;26.","DOI":"10.52586\/4952"},{"key":"799_CR13","doi-asserted-by":"crossref","unstructured":"Newman JC, Verdin E. \u03b2-Hydroxybutyrate: a signaling metabolite. Ann Rev Psychol Nutr. 2017;37.","DOI":"10.1146\/annurev-nutr-071816-064916"},{"key":"799_CR14","doi-asserted-by":"crossref","unstructured":"Polito R, La Torre ME, Moscatelli F, Cibelli G, Valenzano A, Panaro MA, et al. The ketogenic diet and neuroinflammation: the action of beta-hydroxybutyrate in a microglial cell line. Int J Mol Sci. 2023;24(4).","DOI":"10.3390\/ijms24043102"},{"key":"799_CR15","doi-asserted-by":"crossref","unstructured":"Puchalska P, Nelson AB, Stagg DB, Crawford PA. Determination of ketone bodies in biological samples via rapid UPLC-MS\/MS. Talanta. 2021;225.","DOI":"10.1016\/j.talanta.2020.122048"},{"key":"799_CR16","doi-asserted-by":"crossref","unstructured":"Wheless JW. History of the ketogenic diet. Epilepsia. 2008.","DOI":"10.1111\/j.1528-1167.2008.01821.x"},{"key":"799_CR17","doi-asserted-by":"crossref","unstructured":"Bailey EE, Pfeifer HH, Thiele EA. The use of diet in the treatment of epilepsy. Epilepsy and Behavior 2005;6.","DOI":"10.1016\/j.yebeh.2004.10.006"},{"key":"799_CR18","doi-asserted-by":"crossref","unstructured":"Sampaio LP de B. Ketogenic diet for epilepsy treatment. Arquivos de Neuro-Psiquiatria. 2016;74.","DOI":"10.1590\/0004-282X20160116"},{"key":"799_CR19","doi-asserted-by":"crossref","unstructured":"Kossoff EH, Krauss GL, McGrogan JR, Freeman JM. Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology. 2003;61(12).","DOI":"10.1212\/01.WNL.0000098889.35155.72"},{"key":"799_CR20","doi-asserted-by":"crossref","unstructured":"Pietrzak D, Kasperek K, R\u0119kawek P, Pi\u0105tkowska-Chmiel I. The therapeutic role of ketogenic diet in neurological disorders. Nutrients. 2022;14.","DOI":"10.3390\/nu14091952"},{"key":"799_CR21","doi-asserted-by":"crossref","unstructured":"Liu YMC. Medium-chain triglyceride (MCT) ketogenic therapy. Epilepsia. 2008.","DOI":"10.1111\/j.1528-1167.2008.01830.x"},{"key":"799_CR22","doi-asserted-by":"crossref","unstructured":"Ota M, Matsuo J, Ishida I, Takano H, Yokoi Y, Hori H, et al. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer\u2019s disease. Neurosci Lett. 2019;690.","DOI":"10.1016\/j.neulet.2018.10.048"},{"key":"799_CR23","doi-asserted-by":"crossref","unstructured":"Guarnotta V, Emanuele F, Amodei R, Giordano C. Very low-calorie ketogenic diet: a potential application in the treatment of hypercortisolism comorbidities. Nutrients. 2022;14.","DOI":"10.3390\/nu14122388"},{"key":"799_CR24","doi-asserted-by":"crossref","unstructured":"Muzykewicz DA, Lyczkowski DA, Memon N, Conant KD, Pfeifer HH, Thiele EA. Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy. Epilepsia. 2009;50(5).","DOI":"10.1111\/j.1528-1167.2008.01959.x"},{"key":"799_CR25","doi-asserted-by":"crossref","unstructured":"Kysel P, Haluz\u00edkov\u00e1 D, Dole\u017ealov\u00e1 RP, La\u0148kov\u00e1 I, Lacinov\u00e1 Z, Kasperov\u00e1 BJ, et al. The influence of cyclical ketogenic reduction diet vs. Nutritionally balanced reduction diet on body composition, strength, and endurance performance in healthy young males: a randomized controlled trial. Nutrients. 2020;12(9).","DOI":"10.3390\/nu12092832"},{"key":"799_CR26","doi-asserted-by":"crossref","unstructured":"W\u0142odarek D. Role of ketogenic diets in neurodegenerative diseases (Alzheimer\u2019s disease and Parkinson\u2019s disease). Nutrients. 2019;11.","DOI":"10.3390\/nu11010169"},{"key":"799_CR27","doi-asserted-by":"crossref","unstructured":"Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases. In: Pathogenesis and treatment. CNS Neuroscience and Therapeutics 2017;23.","DOI":"10.1111\/cns.12655"},{"key":"799_CR28","doi-asserted-by":"crossref","unstructured":"Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson\u2019s disease. J Educ Chang Parkinson\u2019s Disease. 2013;3.","DOI":"10.3233\/JPD-130230"},{"key":"799_CR29","doi-asserted-by":"crossref","unstructured":"Burr\u00e9 J. The synaptic function of \u03b1-synuclein. J Educ Chang Parkinson\u2019s Disease. 2015;5.","DOI":"10.3233\/JPD-150642"},{"key":"799_CR30","doi-asserted-by":"crossref","unstructured":"Isik S, Yeman Kiyak B, Akbayir R, Seyhali R, Arpaci T. Microglia mediated neuroinflammation in Parkinson\u2019s disease. Cells; 2023;12.","DOI":"10.3390\/cells12071012"},{"key":"799_CR31","doi-asserted-by":"crossref","unstructured":"He J, Zhu G, Wang G, Zhang F. Oxidative stress and neuroinflammation potentiate each other to promote progression of dopamine neurodegeneration. Oxidative Medicine and Cellular Longevity; 2020;2020.","DOI":"10.1155\/2020\/6137521"},{"key":"799_CR32","doi-asserted-by":"crossref","unstructured":"Fu SP, Wang JF, Xue WJ, Liu HM, Run LB, Zeng YL, et al. Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson\u2019s disease models are mediated by GPR109A-dependent mechanisms. J Neuroinflammation. 2015;12(1).","DOI":"10.1186\/s12974-014-0230-3"},{"key":"799_CR33","doi-asserted-by":"crossref","unstructured":"Jiang Z, Yin X, Wang M, Chen T, Wang Y, Gao Z, et al. Effects of ketogenic diet on neuroinflammation in neurodegenerative diseases. Aging Dis. 2022;13.","DOI":"10.14336\/AD.2021.1217"},{"key":"799_CR34","doi-asserted-by":"crossref","unstructured":"Yang X, Cheng B. Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity. J Mol Neurosci. 2010;42(2).","DOI":"10.1007\/s12031-010-9336-y"},{"key":"799_CR35","doi-asserted-by":"crossref","unstructured":"Zhang W, Chen S, Huang X, Tong H, Niu H, Lu L. Neuroprotective effect of a medium-chain triglyceride ketogenic diet on MPTP-induced Parkinson\u2019s disease mice: a combination of transcriptomics and metabolomics in the substantia nigra and fecal microbiome. Cell Death Discov. 2023;9(1).","DOI":"10.1038\/s41420-023-01549-0"},{"key":"799_CR36","doi-asserted-by":"crossref","unstructured":"Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3).","DOI":"10.1038\/nm.3804"},{"key":"799_CR37","doi-asserted-by":"crossref","unstructured":"Qiao G, Lv T, Zhang M, Chen P, Sun Q, Zhang J, et al. \u03b2-hydroxybutyrate (\u03b2-HB) exerts anti-inflammatory and antioxidant effects in lipopolysaccharide (LPS)-stimulated macrophages in Liza haematocheila. Fish Shellfish Immunol. 2020;107.","DOI":"10.1016\/j.fsi.2020.11.005"},{"key":"799_CR38","doi-asserted-by":"crossref","unstructured":"Neudorf H, Islam H, Falkenhain K, Oliveira B, Jackson GS, Moreno-Caba\u00f1as A, et al. Effect of the ketone beta-hydroxybutyrate on markers of inflammation and immune function in adults with type 2 diabetes. Clin Exp Immunol. 2024;216(1).","DOI":"10.1093\/cei\/uxad138"},{"key":"799_CR39","doi-asserted-by":"crossref","unstructured":"Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, et al. Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science (1979). 2013;339:6116.","DOI":"10.1126\/science.1227166"},{"key":"799_CR40","doi-asserted-by":"crossref","unstructured":"Gough SM, Casella A, Ortega KJ, Hackam AS. Neuroprotection by the ketogenic diet: evidence and controversies. Frontiers in Nutrition. 2021;8.","DOI":"10.3389\/fnut.2021.782657"},{"key":"799_CR41","doi-asserted-by":"crossref","unstructured":"Lin C, Chao H, Li Z, Xu X, Liu Y, Bao Z, et al. Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury. Exp Neurol. 2017;290.","DOI":"10.1016\/j.expneurol.2017.01.005"},{"key":"799_CR42","doi-asserted-by":"crossref","unstructured":"Harun-Or-Rashid M, Inman DM. Reduced AMPK activation and increased HCAR activation drive anti-inflammatory response and neuroprotection in glaucoma. J Neuroinflammation. 2018;15(1).","DOI":"10.1186\/s12974-018-1346-7"},{"key":"799_CR43","doi-asserted-by":"crossref","unstructured":"Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10.","DOI":"10.1038\/nri2725"},{"key":"799_CR44","doi-asserted-by":"crossref","unstructured":"Zhu Y, Tang X, Cheng Z, Dong Q, Ruan G. The anti-inflammatory effect of preventive intervention with ketogenic diet mediated by the histone acetylation of mGlur5 promotor region in rat Parkinson\u2019s disease model: a dual-tracer PET study. Parkinsons Dis. 2022;2022.","DOI":"10.1155\/2022\/3506213"},{"key":"799_CR45","doi-asserted-by":"crossref","unstructured":"Reyes NA, Fisher JK, Austgen K, VandenBerg S, Huang EJ, Oakes SA. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest. 2010;120(10).","DOI":"10.1172\/JCI42986"},{"key":"799_CR46","doi-asserted-by":"crossref","unstructured":"Lewitt PA. Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Movement Disorders; 2015;30.","DOI":"10.1002\/mds.26082"},{"key":"799_CR47","doi-asserted-by":"crossref","unstructured":"Puchowicz MA, Zechel JL, Valerio J, Emancipator DS, Xu K, Pundik S, et al. Neuroprotection in diet-induced ketotic rat brain after focal ischemia. J Cereb Blood Flow Metab. 2008;28(12).","DOI":"10.1038\/jcbfm.2008.79"},{"key":"799_CR48","doi-asserted-by":"crossref","unstructured":"Tao Y, Leng SX, Zhang H. Ketogenic diet: an effective treatment approach for neurodegenerative diseases. Curr Neuropharmacol. 2022;20(12).","DOI":"10.2174\/1570159X20666220830102628"},{"key":"799_CR49","doi-asserted-by":"crossref","unstructured":"Noh HS, Kim YS, Kim YH, Han JY, Park CH, Kang AK, et al. Ketogenic diet protects the hippocampus from kainic acid toxicity by inhibiting the dissociation of bad from 14-3-3. J Neurosci Res. 2006;84(8).","DOI":"10.1002\/jnr.21057"},{"key":"799_CR50","doi-asserted-by":"crossref","unstructured":"Choi EH, Kim MH, Park SJ. Targeting mitochondrial dysfunction and reactive oxygen species for neurodegenerative disease treatment. Int J Mol Sci. 2024, Jul, 21;25(14).","DOI":"10.3390\/ijms25147952"},{"key":"799_CR51","doi-asserted-by":"crossref","unstructured":"Jeon BT, Lee DH, Kim KH, Kim HJ, Kang SS, Cho GJ, et al. Ketogenic diet attenuates kainic acid-induced hippocampal cell death by decreasing AMPK\/ACC pathway activity and HSP70. Neurosci Lett. 2009;453(1).","DOI":"10.1016\/j.neulet.2009.01.068"},{"key":"799_CR52","doi-asserted-by":"crossref","unstructured":"Norwitz NG, Hu MT, Clarke K. The mechanisms by which the ketone body d-\u03b2-hydroxybutyrate may improve the multiple cellular pathologies of Parkinson\u2019s disease. Front Nutr. 2019;6.","DOI":"10.3389\/fnut.2019.00063"},{"key":"799_CR53","doi-asserted-by":"crossref","unstructured":"Mustapha M, Taib CNM. MPTP-induced mouse model of Parkinson\u2019s disease: a promising direction for therapeutic strategies. Bosn J Basic Med Sci. 2021;21(4).","DOI":"10.17305\/bjbms.2020.5181"},{"key":"799_CR54","doi-asserted-by":"crossref","unstructured":"Irfannuddin I, Sarahdeaz SFP, Murti K, Santoso B, Koibuchi N. The effect of ketogenic diets on neurogenesis and apoptosis in the dentate gyrus of the male rat hippocampus. J Physiol Sci. 2021;71(1).","DOI":"10.1186\/s12576-020-00786-7"},{"key":"799_CR55","doi-asserted-by":"crossref","unstructured":"Veyrat-Durebex C, Reynier P, Procaccio V, Hergesheimer R, Corcia P, andres CR, et al. How can a ketogenic diet improve motor function? Front Mol Neurosci. 2018;11.","DOI":"10.3389\/fnmol.2018.00015"},{"key":"799_CR56","doi-asserted-by":"crossref","unstructured":"Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Du YS, et al. D-\u03b2-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003;112(6).","DOI":"10.1172\/JCI200318797"},{"key":"799_CR57","doi-asserted-by":"crossref","unstructured":"Jiang Z, Wang X, Zhang H, Yin J, Zhao P, Yin Q, et al. Ketogenic diet protects MPTP-induced mouse model of Parkinson\u2019s disease via altering gut microbiota and metabolites. Medcomm (Beijing). 2023;4(3).","DOI":"10.1002\/mco2.268"},{"key":"799_CR58","doi-asserted-by":"crossref","unstructured":"Parker WD, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson\u2019s disease frontal cortex. Brain Res. 2008;1189(1).","DOI":"10.1016\/j.brainres.2007.10.061"},{"key":"799_CR59","doi-asserted-by":"crossref","unstructured":"Kim DY, Vallejo J, Rho JM. Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors. J Neurochem. 2010;114(1).","DOI":"10.1111\/j.1471-4159.2010.06728.x"},{"key":"799_CR60","doi-asserted-by":"crossref","unstructured":"Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-\u03b2-hydroxybutyrate protects neurons in models of Alzheimer\u2019s and Parkinson\u2019s disease. Proc Natl Acad Sci USA. 2000;97(10).","DOI":"10.1073\/pnas.97.10.5440"},{"key":"799_CR61","doi-asserted-by":"crossref","unstructured":"Cheng B, Yang X, An L, Gao B, Liu X, Liu S. Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson\u2019s disease. Brain Res. 2009;1286.","DOI":"10.1016\/j.brainres.2009.06.060"},{"key":"799_CR62","doi-asserted-by":"crossref","unstructured":"Frey S, Geffroy G, Desquiret-Dumas V, Gueguen N, Bris C, Belal S, et al. The addition of ketone bodies alleviates mitochondrial dysfunction by restoring complex I assembly in a MELAS cellular model. Biochim Biophys Acta Mol Basis Dis. 2017;1863(1).","DOI":"10.1016\/j.bbadis.2016.10.028"},{"key":"799_CR63","doi-asserted-by":"crossref","unstructured":"Ushio-Fukai M, Ash D, Nagarkoti S, Belin De Chantem\u00e8le EJ, Fulton DJR, Fukai T. Interplay between reactive Oxygen\/reactive nitrogen species and metabolism in vascular biology and disease. Antioxid & Redox Signaling. 2021;34.","DOI":"10.1089\/ars.2020.8161"},{"key":"799_CR64","doi-asserted-by":"crossref","unstructured":"Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21.","DOI":"10.1038\/s41580-020-0230-3"},{"key":"799_CR65","doi-asserted-by":"crossref","unstructured":"Weidinger A, Kozlov AV. Biological activities of reactive oxygen and nitrogen species: oxidative stress versus signal transduction. Biomolecules. 2015;5.","DOI":"10.3390\/biom5020472"},{"key":"799_CR66","doi-asserted-by":"crossref","unstructured":"Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD. The role of reactive oxygen species in the pathogenesis of Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease: a mini review. Oxidative Med Cell Longev. 2016;2016.","DOI":"10.1155\/2016\/8590578"},{"key":"799_CR67","doi-asserted-by":"crossref","unstructured":"Alexander GE. Biology of Parkinson\u2019s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci. 2004;6.","DOI":"10.31887\/DCNS.2004.6.3\/galexander"},{"key":"799_CR68","doi-asserted-by":"crossref","unstructured":"Sullivan PG, Rippy NA, Dorenbos K, Concepcion RC, Agarwal AK, Rho JM. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol. 2004;55(4).","DOI":"10.1002\/ana.20062"},{"key":"799_CR69","doi-asserted-by":"crossref","unstructured":"Jeong EA, Jeon BT, Shin HJ, Kim N, Lee DH, Kim HJ, et al. Ketogenic diet-induced peroxisome proliferator-activated receptor-\u03b3 activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures. Exp Neurol. 2011;232(2).","DOI":"10.1016\/j.expneurol.2011.09.001"},{"key":"799_CR70","doi-asserted-by":"crossref","unstructured":"Hoang T, Kuljanin M, Smith MD, Jelokhani-Niaraki M. A biophysical study on molecular physiology of the uncoupling proteins of the central nervous system. Biosci Rep. 2015;35(4).","DOI":"10.1042\/BSR20150130"},{"key":"799_CR71","doi-asserted-by":"crossref","unstructured":"Mercola J. Reductive stress and mitochondrial dysfunction: the hidden link in chronic disease. Free Radic Biol Med. 2025, Jun;233:118\u201331.","DOI":"10.1016\/j.freeradbiomed.2025.03.029"},{"key":"799_CR72","doi-asserted-by":"crossref","unstructured":"Noh HS, Hah YS, Nilufar R, Han J, Bong JH, Kang SS, et al. Acetoacetate protects neuronal cells from oxidative glutamate toxicity. J Neurosci Res. 2006;83(4).","DOI":"10.1002\/jnr.20736"},{"key":"799_CR73","doi-asserted-by":"crossref","unstructured":"Maalouf M, Sullivan PG, Davis L, Kim DY, Rho JM. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience. 2007;145(1).","DOI":"10.1016\/j.neuroscience.2006.11.065"},{"key":"799_CR74","doi-asserted-by":"crossref","unstructured":"Masino SA, Rho JM. Mechanisms of ketogenic diet action. 2012.","DOI":"10.1093\/med\/9780199746545.003.0078"},{"key":"799_CR75","doi-asserted-by":"crossref","unstructured":"Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21228767"},{"key":"799_CR76","doi-asserted-by":"crossref","unstructured":"Mujica-Parodi LR, Amgalan A, Sultan SF, Antal B, Sun X, Skiena S, et al. Diet modulates brain network stability, a biomarker for brain aging, in young adults. Proc Natl Acad Sci USA. 2020;117(11).","DOI":"10.1073\/pnas.1913042117"},{"key":"799_CR77","doi-asserted-by":"crossref","unstructured":"Svart M, Gormsen LC, Hansen J, Zeidler D, Gejl M, Vang K, et al. Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron emission tomography. A randomized, controlled trial. PLoS One. 2018;13(2).","DOI":"10.1371\/journal.pone.0190556"},{"key":"799_CR78","doi-asserted-by":"crossref","unstructured":"Mu J, Wang T, Li M, Guan T, Guo Y, Zhang X, et al. Ketogenic diet protects myelin and axons in diffuse axonal injury. Nutr Neurosci. 2022;25(7).","DOI":"10.1080\/1028415X.2021.1875300"},{"key":"799_CR79","doi-asserted-by":"crossref","unstructured":"Leino RL, Gerhart DZ, Duelli R, Enerson BE, Drewes LR. Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. Neurochem Int. 2001;38(6).","DOI":"10.1016\/S0197-0186(00)00102-9"},{"key":"799_CR80","doi-asserted-by":"crossref","unstructured":"Cheng CM, Kelley B, Wang J, Strauss D, Eagles DA, Bondy CA. A ketogenic diet increases brain insulin-like growth factor receptor and glucose transporter gene expression. Endocrinology. 2003.","DOI":"10.1210\/en.2002-0057"},{"key":"799_CR81","doi-asserted-by":"crossref","unstructured":"Mel\u00f8 TM, Nehlig A, Sonnewald U. Neuronal-glial interactions in rats fed a ketogenic diet. Neurochem Int. 2006;48(6\u20137).","DOI":"10.1016\/j.neuint.2005.12.037"},{"key":"799_CR82","doi-asserted-by":"crossref","unstructured":"Danbolt NC. Glutamate uptake. Prog In Neurobiol. 2001;65.","DOI":"10.1016\/S0301-0082(00)00067-8"},{"key":"799_CR83","doi-asserted-by":"crossref","unstructured":"Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol. 2015;220.","DOI":"10.1007\/978-3-642-45106-5_9"},{"key":"799_CR84","doi-asserted-by":"crossref","unstructured":"Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RAJO, Bromberg E, de Vries Efj. Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation. Mol Neurobiol. 2019;56.","DOI":"10.1007\/s12035-018-1283-6"},{"key":"799_CR85","doi-asserted-by":"crossref","unstructured":"Palasz E, Wysocka A, Gasiorowska A, Chalimoniuk M, Niewiadomski W, Niewiadomska G. BDNF as a promising therapeutic agent in Parkinson\u2019s disease. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21031170"},{"key":"799_CR86","doi-asserted-by":"crossref","unstructured":"Williams LJ, Griffith J, Waller SE, Kwan VP, Fung VSC. The profound impact of gastrointestinal stasis on levodopa response in Parkinson\u2019s disease. Mov Disord Clin Pract. 2022;9(3).","DOI":"10.1002\/mdc3.13425"},{"key":"799_CR87","doi-asserted-by":"crossref","unstructured":"Mantri S, Lepore M, Edison B, Daeschler M, Kopil C, Marras C, et al. The experience of OFF periods in Parkinson\u2019s disease: descriptions, triggers, and alleviating factors. J Patient Cent Res Rev. 2021;8(3).","DOI":"10.17294\/2330-0698.1836"},{"key":"799_CR88","doi-asserted-by":"crossref","unstructured":"Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2020;76.","DOI":"10.1016\/j.parkreldis.2020.05.001"},{"key":"799_CR89","doi-asserted-by":"crossref","unstructured":"Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent H\u00c7, Aureli F, et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease. Eur J Criminol Neurol. 2023;30.","DOI":"10.1111\/ene.15734"},{"key":"799_CR90","doi-asserted-by":"crossref","unstructured":"Boelens Keun JT, Arnoldussen IA, Vriend C, Van De Rest O. Dietary approaches to improve efficacy and control side effects of levodopa therapy in Parkinson\u2019s disease: a systematic review. Advances in Nutrition. 2021;12.","DOI":"10.1093\/advances\/nmab060"},{"key":"799_CR91","doi-asserted-by":"crossref","unstructured":"Wang L, Xiong N, Huang J, Guo S, Liu L, Han C, et al. Protein-restricted diets for ameliorating motor fluctuations in Parkinson\u2019s disease. Front Aging Neurosci. 2017;9.","DOI":"10.3389\/fnagi.2017.00206"},{"key":"799_CR92","doi-asserted-by":"crossref","unstructured":"Melzer TR, Stark MR, Keenan RJ, Myall DJ, MacAskill MR, Pitcher TL, et al. Beta amyloid deposition is not associated with cognitive impairment in Parkinson\u2019s disease. Front Neurol. 2019;10(APR).","DOI":"10.3389\/fneur.2019.00391"},{"key":"799_CR93","doi-asserted-by":"crossref","unstructured":"Kim J, Ghadery C, Cho SS, Mihaescu A, Christopher L, Valli M, et al. Network patterns of Beta-amyloid Deposition in Parkinson\u2019s disease. Mol Neurobiol. 2019;56(11).","DOI":"10.1007\/s12035-019-1625-z"},{"key":"799_CR94","doi-asserted-by":"crossref","unstructured":"Hall S, \u00d6hrfelt A, Constantinescu R, andreasson U, Surova Y, Bostrom F, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or Parkinsonian disorders. Arch Neurol. 2012;69(11).","DOI":"10.1001\/archneurol.2012.1654"},{"key":"799_CR95","doi-asserted-by":"crossref","unstructured":"Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci. 2013;14.","DOI":"10.1038\/nrn3549"},{"key":"799_CR96","doi-asserted-by":"crossref","unstructured":"Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72(4).","DOI":"10.1002\/ana.23659"},{"key":"799_CR97","doi-asserted-by":"crossref","unstructured":"Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. Biomarker discovery for Alzheimer\u2019s disease, frontotemporal lobar degeneration, and Parkinson\u2019s disease. Acta Neuropathologica; 2010;12.","DOI":"10.1007\/s00401-010-0723-9"},{"key":"799_CR98","doi-asserted-by":"crossref","unstructured":"Beauchamp LC, Chan J, Hung LW, Padman BS, Vella LJ, Liu XM, et al. Ablation of tau causes an olfactory deficit in a murine model of Parkinson\u2019s disease. Acta Neuropathol Commun. 2018;6(1).","DOI":"10.1186\/s40478-018-0560-y"},{"key":"799_CR99","doi-asserted-by":"crossref","unstructured":"Singh B, Covelo A, Martell-Mart\u00ednez H, Nanclares C, Sherman MA, Okematti E, et al. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy. Acta Neuropathol. 2019;138(4).","DOI":"10.1007\/s00401-019-02032-w"},{"key":"799_CR100","doi-asserted-by":"crossref","unstructured":"Kashiwaya Y, Bergman C, Lee JH, Wan R, King MT, Mughal MR, et al. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer\u2019s disease. Neurobiol of Aging. 2013;34(6).","DOI":"10.1016\/j.neurobiolaging.2012.11.023"},{"key":"799_CR101","doi-asserted-by":"crossref","unstructured":"Van Der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer\u2019s disease. Nutr Metab (Lond). 2005;2.","DOI":"10.1186\/1743-7075-2-28"},{"key":"799_CR102","doi-asserted-by":"crossref","unstructured":"Yudkoff M, Daikhin Y, Nissim I, Horyn O, Lazarow A, Luhovyy B, et al. Response of brain amino acid metabolism to ketosis. In: Neurochem int. SPEC. ISS.; 2005. p. 47(1\u20132).","DOI":"10.1016\/j.neuint.2005.04.014"},{"key":"799_CR103","doi-asserted-by":"crossref","unstructured":"Brownlow ML, Benner L, D\u2019Agostino D, Gordon MN, Morgan D. Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer\u2019s pathology. PLoS One. 2013;8(9).","DOI":"10.1371\/journal.pone.0075713"},{"key":"799_CR104","doi-asserted-by":"crossref","unstructured":"Augustin K, Khabbush A, Williams S, Eaton S, Orford M, Cross JH, et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. The Lancet Neurology; 2018;17.","DOI":"10.1016\/S1474-4422(17)30408-8"},{"key":"799_CR105","doi-asserted-by":"crossref","unstructured":"Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer\u2019s disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019;47.","DOI":"10.2139\/ssrn.3363786"},{"key":"799_CR106","doi-asserted-by":"crossref","unstructured":"Neth BJ, Mintz A, Whitlow C, Jung Y, Solingapuram Sai K, Register TC, et al. Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer\u2019s disease: a pilot study. Neurobiol of Aging. 2020;86.","DOI":"10.1016\/j.neurobiolaging.2019.09.015"},{"key":"799_CR107","doi-asserted-by":"crossref","unstructured":"Alfonsetti M, Castelli V, D\u2019angelo M. Are we what we eat? Impact of diet on the gut-brain Axis in Parkinson\u2019s disease. Nutrients. 2022;14.","DOI":"10.3390\/nu14020380"},{"key":"799_CR108","doi-asserted-by":"crossref","unstructured":"Santangelo A, Corsello A, Spolidoro GCI, Trovato CM, Agostoni C, Orsini A, et al. The influence of ketogenic diet on gut microbiota: potential benefits. Risks and Indications. Nutrients. 2023;15.","DOI":"10.3390\/nu15173680"},{"key":"799_CR109","doi-asserted-by":"crossref","unstructured":"Soca\u0142a K, Doboszewska U, Szopa A, Serefko A, W\u0142odarczyk M, Zieli\u0144ska A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res. 2021;172.","DOI":"10.1016\/j.phrs.2021.105840"},{"key":"799_CR110","unstructured":"Cryan JF, O\u2019Riordan KJ, Cowan CSM, Sandhu K V, Bastiaanssen TFS, Boehme M, et al. The microbiota-Gut-brain Axis. Physiol Rev. 2019, Oct, 1;99(4):1877\u20132013."},{"key":"799_CR111","doi-asserted-by":"crossref","unstructured":"Poirier AA, Aub\u00e9 B, C\u00f4t\u00e9 M, Morin N, Di Paolo T, Soulet D. Gastrointestinal dysfunctions in Parkinson\u2019s disease: symptoms and treatments. Parkinson\u2019s Disease. 2016;2016.","DOI":"10.1155\/2016\/6762528"},{"key":"799_CR112","doi-asserted-by":"crossref","unstructured":"Kim JS, Sung HY. Gastrointestinal autonomic dysfunction in patients with Parkinson\u2019s disease. J Mov Disord. 2015;8(2).","DOI":"10.14802\/jmd.15008"},{"key":"799_CR113","doi-asserted-by":"crossref","unstructured":"Mulak A, Koszewicz M, Panek-Jeziorna M, Koziorowska-Gawron E, Budrewicz S. Fecal calprotectin as a marker of the gut immune system activation is elevated in Parkinson\u2019s disease. Front Neurosci. 2019;13(SEP).","DOI":"10.3389\/fnins.2019.00992"},{"key":"799_CR114","doi-asserted-by":"crossref","unstructured":"Hui KY, Fernandez-Hernandez H, Hu J, Schaffner A, Pankratz N, Hsu NY, et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn\u2019s disease and Parkinson\u2019s disease. Sci Transl Med. 2018;10(423).","DOI":"10.1126\/scitranslmed.aai7795"},{"key":"799_CR115","doi-asserted-by":"crossref","unstructured":"Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Juzwiak S, Kurzawski G, et al. CARD15 variants in patients with sporadic Parkinson\u2019s disease. Neurosci Res. 2007;57(3).","DOI":"10.1016\/j.neures.2006.11.012"},{"key":"799_CR116","doi-asserted-by":"crossref","unstructured":"Li W, Zhao Q, Wang J, Wang Y, Wen T. Dcf1 deletion presents alterations in gut microbiota of mice similar to Parkinson\u2019s disease. Biochem Biophys Res Commun. 2020;529(4).","DOI":"10.1016\/j.bbrc.2020.06.150"},{"key":"799_CR117","doi-asserted-by":"crossref","unstructured":"Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJA, Kraneveld AD. Exploring Braak\u2019s hypothesis of Parkinson\u2019s disease. Front Neurol. 2017;8(FEB).","DOI":"10.3389\/fneur.2017.00037"},{"key":"799_CR118","doi-asserted-by":"crossref","unstructured":"Braak H, R\u00fcb U, Gai WP, Del Tredici K. Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110(5).","DOI":"10.1007\/s00702-002-0808-2"},{"key":"799_CR119","doi-asserted-by":"crossref","unstructured":"Del Tredici K, Braak H. Sporadic Parkinson\u2019s disease: development and distribution of \u03b1-synuclein pathology. Neuropathol Appl Neurobiol. 2016;42.","DOI":"10.1111\/nan.12298"},{"key":"799_CR120","doi-asserted-by":"crossref","unstructured":"Hawkes CH, Del Tredici K, Braak H. Parkinson\u2019s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33.","DOI":"10.1111\/j.1365-2990.2007.00874.x"},{"key":"799_CR121","doi-asserted-by":"crossref","unstructured":"Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson\u2019s disease? Evidence from 3 cases. Mov Disord. 2012;27(6).","DOI":"10.1002\/mds.25020"},{"key":"799_CR122","doi-asserted-by":"crossref","unstructured":"Liu Y, Forsythe P. Vagotomy and insights into the microbiota-gut-brain axis. Neurosci Res. 2021;168.","DOI":"10.1016\/j.neures.2021.04.001"},{"key":"799_CR123","doi-asserted-by":"crossref","unstructured":"Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, et al. Vagotomy and Parkinson disease a Swedish register-based matched-cohort study. Neurology. 2017;88(21).","DOI":"10.1212\/WNL.0000000000003961"},{"key":"799_CR124","doi-asserted-by":"crossref","unstructured":"Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bj\u00f6rklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014;128(6).","DOI":"10.1007\/s00401-014-1343-6"},{"key":"799_CR125","doi-asserted-by":"crossref","unstructured":"Arotcarena ML, Dovero S, Prigent A, Bourdenx M, Camus S, Porras G, et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain. 2020;143(5).","DOI":"10.1093\/brain\/awaa096"},{"key":"799_CR126","doi-asserted-by":"crossref","unstructured":"Beach TG, Adler CH, Sue LI, Shill HA, Driver-Dunckley E, Mehta SH, et al. Vagus nerve and stomach synucleinopathy in Parkinson\u2019s disease, incidental lewy body disease, and normal elderly subjects: evidence against the \u201cbody-first\u201d. Hypothesis. J Parkinsons Dis. 2021;11(4).","DOI":"10.3233\/JPD-212733"},{"key":"799_CR127","doi-asserted-by":"crossref","unstructured":"Santos SF, De Oliveira HL, Yamada ES, Neves BC, Pereira A. The gut and Parkinson\u2019s disease - a bidirectional pathway. Front Neurol. 2019;10.","DOI":"10.3389\/fneur.2019.00574"},{"key":"799_CR128","doi-asserted-by":"crossref","unstructured":"Wang L, Cui Y, Han B, Du Y, Salewala KS, Wang S, et al. Gut microbiota and Parkinson\u2019s disease. Chin Med J (Engl). 2025, Feb, 5;138(3):289\u201397.","DOI":"10.1097\/CM9.0000000000003318"},{"key":"799_CR129","doi-asserted-by":"crossref","unstructured":"Varesi A, Campagnoli LIM, Fahmideh F, Pierella E, Romeo M, Ricevuti G, et al. The interplay between gut microbiota and Parkinson\u2019s disease: implications on diagnosis and treatment. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms232012289"},{"key":"799_CR130","doi-asserted-by":"crossref","unstructured":"Zhang X, Tang B, Guo J. Parkinson\u2019s disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Translational Neurodegeneration. 2023;12.","DOI":"10.1186\/s40035-023-00392-8"},{"key":"799_CR131","doi-asserted-by":"crossref","unstructured":"Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1).","DOI":"10.3390\/microorganisms7010014"},{"key":"799_CR132","doi-asserted-by":"crossref","unstructured":"Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Mov Disord. 2011;26(5).","DOI":"10.1002\/mds.23566"},{"key":"799_CR133","doi-asserted-by":"crossref","unstructured":"Scheperjans F, Derkinderen P, Borghammer P. The gut and Parkinson\u2019s disease: Hype or hope? J Educ Chang Parkinson\u2019s Disease. 2018;8.","DOI":"10.3233\/JPD-181477"},{"key":"799_CR134","doi-asserted-by":"crossref","unstructured":"Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov Disord. 2015;30(3).","DOI":"10.1002\/mds.26069"},{"key":"799_CR135","doi-asserted-by":"crossref","unstructured":"Petrov VA, Saltykova I V, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, et al. Analysis of gut microbiota in patients with Parkinson\u2019s disease. Bull Exp Biol Med. 2017;162(6).","DOI":"10.1007\/s10517-017-3700-7"},{"key":"799_CR136","doi-asserted-by":"crossref","unstructured":"Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021;7(1).","DOI":"10.1038\/s41531-021-00156-z"},{"key":"799_CR137","doi-asserted-by":"crossref","unstructured":"Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW. Parkinsonism: siblings share helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand. 1999;99(1).","DOI":"10.1111\/j.1600-0404.1999.tb00654.x"},{"key":"799_CR138","doi-asserted-by":"crossref","unstructured":"McGee DJ, Lu XH, Disbrow EA. Stomaching the possibility of a pathogenic role for helicobacter pylori in Parkinson\u2019s disease. J Educ Chang Parkinson\u2019s Disease. 2018;8.","DOI":"10.3233\/JPD-181327"},{"key":"799_CR139","doi-asserted-by":"crossref","unstructured":"Rong WB, Jia ZY, Feng CY, Huang C, Zhang F. Helicobacter pylori infection and Parkinson\u2019s disease: etiology, pathogenesis and levodopa bioavailability. Immunity and Ageing; 2024;21.","DOI":"10.1186\/s12979-023-00404-1"},{"key":"799_CR140","doi-asserted-by":"crossref","unstructured":"Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson\u2019s disease. PLoS One. 2015;10(11).","DOI":"10.1371\/journal.pone.0142164"},{"key":"799_CR141","doi-asserted-by":"crossref","unstructured":"Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson\u2019s disease. Mov Disord. 2015;30(10).","DOI":"10.1002\/mds.26307"},{"key":"799_CR142","doi-asserted-by":"crossref","unstructured":"Caputi V, Giron MC. Microbiome-gut-brain axis and toll-like receptors in Parkinson\u2019s disease. Int J Mol Sci. 2018;19.","DOI":"10.3390\/ijms19061689"},{"key":"799_CR143","doi-asserted-by":"crossref","unstructured":"Lei Q, Wu T, Wu J, Hu X, Guan Y, Wang Y, et al. Roles of \u03b1synuclein in gastrointestinal microbiome dysbiosisrelated Parkinson\u2019s disease progression (review). Molecular Medicine Reports. 2021;24.","DOI":"10.3892\/mmr.2021.12374"},{"key":"799_CR144","doi-asserted-by":"crossref","unstructured":"Baert F, Matthys C, Maselyne J, Van Poucke C, Van Coillie E, Bergmans B, et al. Parkinson\u2019s disease patients\u2019 short chain fatty acids production capacity after in vitro fecal fiber fermentation. NPJ Parkinsons Dis. 2021;7(1).","DOI":"10.1038\/s41531-021-00215-5"},{"key":"799_CR145","doi-asserted-by":"crossref","unstructured":"Andoh A. Physiological role of gut microbiota for maintaining human health. Digestion. 2016;93.","DOI":"10.1159\/000444066"},{"key":"799_CR146","doi-asserted-by":"crossref","unstructured":"Ma D, Wang AC, Parikh I, Green SJ, Hoffman JD, Chlipala G, et al. Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice. Sci Rep. 2018;8(1).","DOI":"10.1038\/s41598-018-25190-5"},{"key":"799_CR147","doi-asserted-by":"crossref","unstructured":"Chen T, Long W, Zhang C, Liu S, Zhao L, Hamaker BR. Fiber-utilizing capacity varies in Prevotella- versus Bacteroides-dominated gut microbiota. Sci Rep. 2017;7(1).","DOI":"10.1038\/s41598-017-02995-4"},{"key":"799_CR148","doi-asserted-by":"crossref","unstructured":"Duncan SH, Louis P, Thomson JM, Flint HJ. The role of pH in determining the species composition of the human colonic microbiota. Environ Microbiol. 2009;11(8).","DOI":"10.1111\/j.1462-2920.2009.01931.x"},{"key":"799_CR149","doi-asserted-by":"crossref","unstructured":"Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Alimentary Pharmacol Ther. 2008;27.","DOI":"10.1111\/j.1365-2036.2007.03562.x"},{"key":"799_CR150","doi-asserted-by":"crossref","unstructured":"Haikal C, Chen QQ, Li JY. Microbiome changes: An indicator of Parkinson\u2019s disease? Transl Neurodegener. 2019;8.","DOI":"10.1186\/s40035-019-0175-7"},{"key":"799_CR151","doi-asserted-by":"crossref","unstructured":"Nishiwaki H, Ito M, Ishida T, Hamaguchi T, Maeda T, Kashihara K, et al. Meta-analysis of gut dysbiosis in Parkinson\u2019s disease. Mov Disord. 2020;35(9).","DOI":"10.1002\/mds.28119"},{"key":"799_CR152","doi-asserted-by":"crossref","unstructured":"Mathewson ND, Jenq R, Mathew A V, Koenigsknecht M, Hanash A, Toubai T, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016;17(5).","DOI":"10.1038\/ni.3400"},{"key":"799_CR153","doi-asserted-by":"crossref","unstructured":"Bourassa MW, Alim I, Bultman SJ, Ratan RR. Butyrate, neuroepigenetics and the gut microbiome: can a high fiber diet improve brain health? Neurosci Lett. 2016;625.","DOI":"10.1016\/j.neulet.2016.02.009"},{"key":"799_CR154","doi-asserted-by":"crossref","unstructured":"Dos Santos EF, Busanello ENB, Miglioranza A, \u00c2 Z, Barchak AG, Vargas CR, et al. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinso\u0144s disease. Metab Brain Dis. 2009;24(2).","DOI":"10.1007\/s11011-009-9139-4"},{"key":"799_CR155","doi-asserted-by":"crossref","unstructured":"Arumugam M, Raes J, Pelletier E, Le PD, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:7346.","DOI":"10.1038\/nature09944"},{"key":"799_CR156","doi-asserted-by":"crossref","unstructured":"Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011;6(10).","DOI":"10.1371\/journal.pone.0025792"},{"key":"799_CR157","doi-asserted-by":"crossref","unstructured":"Queipo-Ortu\u00f1o MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, et al. Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS One. 2013;8(5).","DOI":"10.1371\/journal.pone.0065465"},{"key":"799_CR158","doi-asserted-by":"crossref","unstructured":"andrews ZB, Erion D, Beiler R, Liu ZW, Abizaid A, Zigman J, et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci. 2009;29(45).","DOI":"10.1523\/JNEUROSCI.3890-09.2009"},{"key":"799_CR159","doi-asserted-by":"crossref","unstructured":"Bayliss JA, andrews ZB. Ghrelin is neuroprotective in Parkinson\u2019s disease: molecular mechanisms of metabolic neuroprotection. Ther Adv Endocrinol Metab. 2013;4(1).","DOI":"10.1177\/2042018813479645"},{"key":"799_CR160","doi-asserted-by":"crossref","unstructured":"Ye Y, Xu J, Shen H, Yu Z, Chen G. Neuroprotective effects of hydrogen sulfide in Parkinson\u2019s disease. Med Gas Res. 2024, Sep, 1;14(3):145\u201348.","DOI":"10.4103\/2045-9912.385945"},{"key":"799_CR161","doi-asserted-by":"crossref","unstructured":"Cakmak YO. Provotella-derived hydrogen sulfide, constipation, and neuroprotection in Parkinson\u2019s disease. Movement Disord. 2015;30.","DOI":"10.1002\/mds.26258"},{"key":"799_CR162","doi-asserted-by":"crossref","unstructured":"Barroso A, Mahler JV, Fonseca-Castro PH, Quintana FJ. The aryl hydrocarbon receptor and the gut-brain axis. Cell Mol Immunol. 2021;18.","DOI":"10.1038\/s41423-020-00585-5"},{"key":"799_CR163","doi-asserted-by":"crossref","unstructured":"Iwaniak P, Owe-Larsson M, Microbiota UE. Tryptophan and aryl hydrocarbon receptors as the target triad in Parkinson\u2019s disease-A narrative review. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25052915"},{"key":"799_CR164","doi-asserted-by":"crossref","unstructured":"Lee YH, Lin CH, Hsu PC, Sun YY, Huang YJ, Zhuo JH, et al. Aryl hydrocarbon receptor mediates both proinflammatory and anti-inflammatory effects in lipopolysaccharide-activated microglia. Glia. 2015;63(7).","DOI":"10.1002\/glia.22805"},{"key":"799_CR165","doi-asserted-by":"crossref","unstructured":"Coretti L, Buommino E, Lembo F. The aryl hydrocarbon receptor pathway: a linking bridge between the gut microbiome and neurodegenerative diseases. Front Cell Neurosci. 2024;18:1433747.","DOI":"10.3389\/fncel.2024.1433747"},{"key":"799_CR166","doi-asserted-by":"crossref","unstructured":"Szab\u00f3 N, Kincses ZT, Toldi J, V\u00e9csei L. Altered tryptophan metabolism in Parkinson\u2019s disease: a possible novel therapeutic approach. J Neurol Sci. 2011;310(1\u20132).","DOI":"10.1016\/j.jns.2011.07.021"},{"key":"799_CR167","doi-asserted-by":"crossref","unstructured":"Wang Y, Chen S, Tan J, Gao Y, Yan H, Liu Y, et al. Tryptophan in the diet ameliorates motor deficits in a rotenone-induced rat Parkinson\u2019s disease model via activating the aromatic hydrocarbon receptor pathway. Brain Behav. 2021;11(8).","DOI":"10.1002\/brb3.2226"},{"key":"799_CR168","doi-asserted-by":"crossref","unstructured":"Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson\u2019s disease. Ageing Res Rev. 2018;45.","DOI":"10.1016\/j.arr.2018.04.004"},{"key":"799_CR169","doi-asserted-by":"crossref","unstructured":"Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, et al. Ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 cells. Cell. 2020;181(6).","DOI":"10.1016\/j.cell.2020.04.027"},{"key":"799_CR170","doi-asserted-by":"crossref","unstructured":"Paoli A, Mancin L, Bianco A, Thomas E, Mota JF, Piccini F. Ketogenic diet and microbiota. In: Friends or enemies? Genes. 2019;10.","DOI":"10.3390\/genes10070534"},{"key":"799_CR171","doi-asserted-by":"crossref","unstructured":"Basciani S, Camajani E, Contini S, Persichetti A, Risi R, Bertoldi L, et al. Very-low-calorie ketogenic diets with whey, vegetable, or animal protein in patients with obesity: a randomized Pilot study. J Clin Endocrinol Metab. 2020, Sep, 1;105(9).","DOI":"10.1210\/clinem\/dgaa336"},{"key":"799_CR172","doi-asserted-by":"crossref","unstructured":"Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science (1979). 2011;334:6052.","DOI":"10.1126\/science.1208344"},{"key":"799_CR173","doi-asserted-by":"crossref","unstructured":"Natividad JM, Lamas B, Pham HP, Michel ML, Rainteau D, Bridonneau C, et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat Commun. 2018;9(1).","DOI":"10.1038\/s41467-018-05249-7"},{"key":"799_CR174","doi-asserted-by":"crossref","unstructured":"Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, B\u00e4ckhed F. Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab. 2015;22(4).","DOI":"10.1016\/j.cmet.2015.07.026"},{"key":"799_CR175","doi-asserted-by":"crossref","unstructured":"Huynh VA, Takala TM, Murros KE, Diwedi B, Saris PEJ. Desulfovibrio bacteria enhance alpha-synuclein aggregation in a Caenorhabditis elegans model of Parkinson\u2019s disease. Front Cell Infect Microbiol. 2023;13.","DOI":"10.3389\/fcimb.2023.1181315"},{"key":"799_CR176","doi-asserted-by":"crossref","unstructured":"Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transd and Targ Ther. 2024;9.","DOI":"10.1038\/s41392-024-01743-1"},{"key":"799_CR177","doi-asserted-by":"crossref","unstructured":"Alam M, Abbas K, Mustafa M, Usmani N, Habib S. Microbiome-based therapies for Parkinson\u2019s disease. Front Nutr. 2024;11:1496616.","DOI":"10.3389\/fnut.2024.1496616"},{"key":"799_CR178","doi-asserted-by":"crossref","unstructured":"Heischmann S, Gano LB, Quinn K, Liang LP, Klepacki J, Christians U, et al. Regulation of kynurenine metabolism by a ketogenic diet. J Lipid Res. 2018;59(6).","DOI":"10.1194\/jlr.M079251"},{"key":"799_CR179","doi-asserted-by":"crossref","unstructured":"Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson\u2019s disease: a pilot randomized controlled trial. Mov Disord. 2018;33(8).","DOI":"10.1002\/mds.27390"},{"key":"799_CR180","doi-asserted-by":"crossref","unstructured":"Milder JB, Liang LP, Patel M. Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet. Neurobiol Dis. 2010;40(1).","DOI":"10.1016\/j.nbd.2010.05.030"},{"key":"799_CR181","doi-asserted-by":"crossref","unstructured":"Sharma JC, Lewis A. Weight in Parkinson\u2019s disease: phenotypical significance. Int Rev Neurobiol. 2017.","DOI":"10.1016\/bs.irn.2017.04.011"},{"key":"799_CR182","doi-asserted-by":"crossref","unstructured":"Leehey M, Luo S, Sharma S, Wills AMA, Bainbridge JL, Wong PS, et al. Association of metabolic syndrome and change in unified Parkinson\u2019s disease rating scale scores. Neurology. 2017;89(17).","DOI":"10.1212\/WNL.0000000000004572"},{"key":"799_CR183","doi-asserted-by":"crossref","unstructured":"Krikorian R, Shidler MD, Summer SS, Sullivan PG, Duker AP, Isaacson RS, et al. Nutritional ketosis for mild cognitive impairment in Parkinson\u2019s disease: a controlled pilot trial. Clin Park Relat Disord. 2019;1.","DOI":"10.1016\/j.prdoa.2019.07.006"},{"key":"799_CR184","doi-asserted-by":"crossref","unstructured":"Clark IA, Kim M, Maguire EA. Verbal paired associates and the hippocampus: the role of scenes. J Cogn Neurosci. 2018;30(12).","DOI":"10.1162\/jocn_a_01315"},{"key":"799_CR185","doi-asserted-by":"crossref","unstructured":"Elamin M, Ruskin DN, Masino SA, Sacchetti P. Ketone-based metabolic therapy: is increased nad+ a primary mechanism? Front Mol Neurosci. 2017;10.","DOI":"10.3389\/fnmol.2017.00377"},{"key":"799_CR186","doi-asserted-by":"crossref","unstructured":"Schmoller A, Hass T, Strugovshchikova O, Melchert UH, Scholand-Engler HG, Peters A, et al. Evidence for a relationship between body mass and energy metabolism in the human brain. J Cereb Blood Flow Metab. 2010;30(7).","DOI":"10.1038\/jcbfm.2010.48"},{"key":"799_CR187","doi-asserted-by":"crossref","unstructured":"O\u2019Brien PD, Hinder LM, Callaghan BC, Feldman EL. Neurological consequences of obesity. The Lancet Neur. 2017;16.","DOI":"10.1016\/S1474-4422(17)30084-4"},{"key":"799_CR188","doi-asserted-by":"crossref","unstructured":"Tidman MM, White D, White T. Effects of an low carbohydrate\/healthy fat\/ketogenic diet on biomarkers of health and symptoms, anxiety and depression in Parkinson\u2019s disease: a pilot study. Neurodegener Dis Manag. 2022;12(2).","DOI":"10.2217\/nmt-2021-0033"},{"key":"799_CR189","doi-asserted-by":"crossref","unstructured":"Bostock ECS, Kirkby KC, Taylor B V, Hawrelak JA. Consumer reports of \u201cketo flu\u201d associated with the ketogenic diet. Front Nutr. 2020;7.","DOI":"10.3389\/fnut.2020.00020"},{"key":"799_CR190","doi-asserted-by":"crossref","unstructured":"Tuck CJ, Staudacher HM. The keto diet and the gut: cause for concern? Lancet Gastroenterol Hepatol. 2019;4(12).","DOI":"10.1016\/S2468-1253(19)30353-X"},{"key":"799_CR191","doi-asserted-by":"crossref","unstructured":"Choi AH, Delgado M, Chen KY, Chung ST, Courville A, Turner SA, et al. A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson\u2019s disease. BMC Neurol. 2024 Apr, 1;24(1):106.","DOI":"10.1186\/s12883-024-03603-5"},{"key":"799_CR192","doi-asserted-by":"crossref","unstructured":"Harvey CJDC, Schofield GM, Williden M, McQuillan JA. The effect of medium chain triglycerides on time to nutritional ketosis and symptoms of keto-induction in healthy adults: a randomised controlled clinical trial. J Nutr Metab. 2018;2018.","DOI":"10.1155\/2018\/2630565"},{"key":"799_CR193","doi-asserted-by":"crossref","unstructured":"Rekdal VM, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science (1979). 2019;364:6445.","DOI":"10.1126\/science.aau6323"},{"key":"799_CR194","doi-asserted-by":"crossref","unstructured":"Koyuncu H, Fidan V, Toktas H, Binay O, Celik H. Effect of ketogenic diet versus regular diet on voice quality of patients with Parkinson\u2019s disease. Acta Neurol Belg. 2021;121(6).","DOI":"10.1007\/s13760-020-01486-0"},{"key":"799_CR195","doi-asserted-by":"crossref","unstructured":"Tidman M. Effects of a ketogenic Diet on symptoms, biomarkers, depression, and anxiety in Parkinson\u2019s disease: a case study. Cureus. 2022.","DOI":"10.7759\/cureus.23684"},{"key":"799_CR196","doi-asserted-by":"crossref","unstructured":"VanItallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology. 2005;64(4).","DOI":"10.1212\/01.WNL.0000152046.11390.45"},{"key":"799_CR197","doi-asserted-by":"crossref","unstructured":"Norwitz NG, Sethi S, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020;27.","DOI":"10.1097\/MED.0000000000000564"},{"key":"799_CR198","doi-asserted-by":"crossref","unstructured":"Kverneland M, Selmer KK, Nakken KO, Iversen PO, Taub\u00f8ll E. A prospective study of the modified Atkins diet for adults with idiopathic generalized epilepsy. Epilepsy Behav. 2015;53.","DOI":"10.1016\/j.yebeh.2015.10.021"},{"key":"799_CR199","doi-asserted-by":"crossref","unstructured":"Poorshiri B, Barzegar M, Tahmasebi S, Shiva S, Raeisi S, Ebadi Z. The efficacy comparison of classic ketogenic diet and modified Atkins diet in children with refractory epilepsy: a clinical trial. Acta Neurol Belg. 2021;121(2).","DOI":"10.1007\/s13760-019-01225-0"},{"key":"799_CR200","doi-asserted-by":"crossref","unstructured":"IJff DM, Postulart D, Lambrechts DAJE, Majoie MHJM, de Kinderen RJA, Hendriksen JGM, et al. Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: a randomized controlled trial. Epilepsy Behav. 2016;60.","DOI":"10.1016\/j.yebeh.2016.04.033"},{"key":"799_CR201","doi-asserted-by":"crossref","unstructured":"Lin A, Turner Z, Doerrer SC, Stanfield A, Kossoff EH. Complications during ketogenic diet initiation: prevalence, treatment, and influence on seizure outcomes. Pediatr Neurol. 2017;68.","DOI":"10.1016\/j.pediatrneurol.2017.01.007"},{"key":"799_CR202","doi-asserted-by":"crossref","unstructured":"Wells J, Swaminathan A, Paseka J, Hanson C. Efficacy and safety of a ketogenic diet in children and adolescents with refractory epilepsy-a review. Nutrients. 2020;12.","DOI":"10.3390\/nu12061809"},{"key":"799_CR203","doi-asserted-by":"crossref","unstructured":"Crosby L, Davis B, Joshi S, Jardine M, Paul J, Neola M, et al. Ketogenic diets and chronic disease: weighing the benefits against the risks. Frontiers in Nutri. 2021;8.","DOI":"10.3389\/fnut.2021.702802"},{"key":"799_CR204","doi-asserted-by":"crossref","unstructured":"Zhou C, Wang M, Liang J, He G, Chen N. Ketogenic diet benefits to weight loss, glycemic control, and lipid profiles in overweight patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trails. Int J Multiling Environ Res and Public Health. 2022;19.","DOI":"10.3390\/ijerph191610429"},{"key":"799_CR205","doi-asserted-by":"crossref","unstructured":"Cai QY, Zhou ZJ, Luo R, Gan J, Li SP, Mu DZ, et al. Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies. World J Pediatr. 2017;13.","DOI":"10.1007\/s12519-017-0053-2"},{"key":"799_CR206","doi-asserted-by":"crossref","unstructured":"Hartman AL, Gasior M, Vining EPG, Rogawski MA. The neuropharmacology of the ketogenic diet. Pediatric Neurology. 2007;36.","DOI":"10.1016\/j.pediatrneurol.2007.02.008"},{"key":"799_CR207","doi-asserted-by":"crossref","unstructured":"Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020, Jun, 24;6(6):CD001903.","DOI":"10.1002\/14651858.CD001903.pub5"},{"key":"799_CR208","doi-asserted-by":"crossref","unstructured":"Phillips MCL, Deprez LM, Mortimer GMN, Murtagh DKJ, McCoy S, Mylchreest R, et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer\u2019s disease. Alzheimers Res Ther. 2021;13(1).","DOI":"10.1186\/s13195-021-00783-x"},{"key":"799_CR209","doi-asserted-by":"crossref","unstructured":"Grochowska K, Przeliorz A. The effect of the ketogenic diet on the therapy of neurodegenerative diseases and its impact on improving cognitive functions. Dement Geriatr Cogn Dis Extra. 2022;12(2).","DOI":"10.1159\/000524331"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00799-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00799-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00799-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:01:12Z","timestamp":1764115272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00799-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":209,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00799-2","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}